Francesca Lodi

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers”.

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers

British Journal of Cancer(2023)10.1038/s41416-023-02402-y

N/A

0.553DataRank · unranked

39 citations

Anne Kleijn, Jie Ju, Kevin Jimenez-Cowell, Federica Fabro, Michelle Klein +35 more

Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetes

Journal of Clinical Investigation(2025)10.1172/jci176403

N/A

0.247DataRank · unranked

4 citations

Pierre Lemaître, Laura Martínez-Calvo, Francesca Lodi, Álvaro Cortés Calabuig, Samal Bissenova +10 more